AzTrials
AzTrials

Disorders of Gut-brain InteractioniACTforDGBINCT07814196

Efficacy, and Cost-effectiveness of an Online ACT Intervention for Disorders of Gut-Brain Interaction (iACTforDGBI)

A study testing iACTforDGBI intervention and DGBI School in people with Disorders of Gut-brain Interaction and Distress, Psychological, run by Örebro University, Sweden at 1 site in Sweden.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Test of efficacy and cost-effectiveness of the iACTforDGBI intervention vs an active control group (DGBI School) Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
iACTforDGBI intervention and DGBI School
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteSweden
Study dates
15 Sep 2026to 30 Sep 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age between 18 and 75 years
  • Meeting clinical symptom levels for least one DGBI diagnosis (assessed with the Rome IV Diagnostic Questionnaire for Functional Gastrointestinal Disorders in Adults (Palsson et al., 2016))
  • Stable medication for psychiatric symptoms including anxiety, depression and sleep problems for at least two months prior to intervention.
  • Ability to read and write Swedish
  • Have access to a device (like computer, tablet or smartphone with) with access to the internet and that can be used to attend video conferences and preview the intervention platform (i.e., have a microphone and speakers or headphones).

Who cannot join

  • Currently undergoing any form of psychological intervention.
  • Increased risk of suicide (≥4 points on MADRS item 9).
  • Ongoing or previously diagnosed severe psychiatric disorder, such as schizophrenia spectrum disorders or bipolar disorder.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sweden1 site, 1 recruiting
  • Örebro University

    Örebro, SE-701 82

    Ines Trindade, +46 19 30 30 00, ines.trindade@oru.se

    Recruiting

Other trials in Sweden

About this study

Test of efficacy and cost-effectiveness of the iACTforDGBI intervention vs an active control group (DGBI School)

Being tested
iACTforDGBI intervention, DGBI School

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • iACTforDGBI interventionBehavioural

    Online ACT, mindfulness, and compassion-based intervention, 8 sessions

  • DGBI SchoolOther

    Education on DGBI, diet, and psychological factors

Study groups in NCT07814196
Study groupRoleWhat they receive
iACTforDGBI interventionExperimentalACT, mindfulness, and compassion-based online intervention
Receives: Behavioral: iACTforDGBI intervention
DGBI SchoolActive comparatorEducation on DGBI
Receives: Other: DGBI School

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Depressive symptoms (Patient Health Questionnaire-9, PHQ-9)

    Depressive symptoms measured with the Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report scale. Each item is rated from 0 (not at all) to 3 (nearly every day) and items are summed. Total score ranges from 0 to 27. Higher scores indicate more severe depressive symptoms (worse outcome).

    Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  2. Gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale, GSRS)

    Gastrointestinal symptom severity measured with the Gastrointestinal Symptom Rating Scale (GSRS), a 15-item self-report scale. Each item is rated on a 7-point Likert scale from 1 (no discomfort) to 7 (very severe discomfort), and items are summed. Total score ranges from 15 to 105. Higher scores indicate more severe gastrointestinal symptoms (worse outcome).

    Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  3. Anxiety symptoms (Generalized Anxiety Disorder 7-item scale, GAD-7)

    Anxiety symptoms measured with the Generalized Anxiety Disorder 7-item scale (GAD-7). Each of the 7 items is rated from 0 (not at all) to 3 (nearly every day) and items are summed. Total score ranges from 0 to 21. Higher scores indicate more severe anxiety symptoms (worse outcome).

    Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

Secondary outcomes (11)
  1. Health-related quality of life (EuroQol 5-Dimension 5-Level, EQ-5D-5L)

    Health-related quality of life measured with the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). Five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each with five severity levels, are converted into a single index value using the [Swedish c-TTO value set (Sun et al., 2022) / Swedish experience-based value set (Burström et al., 2020)]. The index is anchored at 1.00 (full health) and 0.00 (a state equivalent to dead), with negative values representing states considered worse than dead; the [Swedish c-TTO value set ranges from -0.31 to 1.00 / Swedish experience-based value set ranges from 0.243 to 0.976]. Higher index values indicate better health-related quality of life (better outcome). The accompanying EQ visual analogue scale ranges from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better self-rated health.

    Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  2. Health-related quality of life (Assessment of Quality of Life-8 Dimensions, AQoL-8D)

    Health-related quality of life measured with the Assessment of Quality of Life-8 Dimensions (AQoL-8D), a 35-item instrument covering eight dimensions (independent living, happiness, mental health, coping, relationships, self-worth, pain, senses). Item responses are converted into a single utility score using the Australian scoring algorithm, on a scale anchored at 1.00 (full health) and 0.00 (dead); the algorithmic range is 0.09 to 1.00. Higher scores indicate better health-related quality of life (better outcome).

    Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  3. Health care use and productivity costs (Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness, TiC-P)

    Health care utilisation and productivity losses measured with the Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness (TiC-P). The TiC-P is not scored as a rating scale: reported numbers of health care contacts and days of absenteeism and reduced productivity are multiplied by Swedish unit costs to yield costs in SEK. The minimum is 0 SEK and there is no fixed maximum. Higher values indicate greater resource use and productivity loss (worse outcome).

    Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  4. Illness-related shame (Chronic Illness-related Shame Scale, CISS)

    Illness-related shame measured with the Chronic Illness-related Shame Scale (CISS), a 7-item unidimensional self-report scale. Each item is rated from 0 (never true) to 4 (always true) and items are summed. Total score ranges from 0 to 28. Higher scores indicate greater illness-related shame (worse outcome).

    Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  5. Psychological flexibility and inflexibility (Multidimensional Psychological Flexibility Inventory, MPFI)

    Items are rated on a 6-point scale from 1 (never true) to 6 (always true). Global psychological flexibility and global psychological inflexibility composite scores are each calculated as the mean of their constituent items, giving a score range of 1 to 6 for each composite. Higher psychological flexibility scores indicate greater flexibility (better outcome); higher psychological inflexibility scores indicate greater inflexibility (worse outcome).

    Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  6. Self-compassion (Self-Compassion Scale-Short Form, SCS-SF)

    Self-compassion measured with the Self-Compassion Scale-Short Form (SCS-SF), a 12-item self-report scale. Items are rated from 1 (almost never) to 5 (almost always); negatively worded items are reverse-scored and the total score is the mean of all items, ranging from 1 to 5. Higher scores indicate greater self-compassion (better outcome).

    Measured: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up

  7. Treatment credibility and expectancy (Credibility/Expectancy Questionnaire, CEQ)

    Treatment credibility and outcome expectancy measured with the Credibility/Expectancy Questionnaire (CEQ), a 6-item self-report measure. The credibility subscale (items 1-3) is rated from 1 (not at all) to 9 (very much) and summed, giving a range of 3 to 27. The expectancy subscale (items 4-6) combines one item rated from 1 to 9 and two items rated from 0% to 100%; these items are standardised and summed, so the subscale has no fixed raw minimum and maximum. Higher scores on both subscales indicate greater perceived treatment credibility and more positive outcome expectancy.

    Measured: Week 0 (only expectancy sub scale), Week 4 (both subscales)

  8. System usability (System Usability Scale, SUS)

    Perceived usability of the online intervention platform measured with the System Usability Scale (SUS), a 10-item self-report scale. Items are rated from 1 (strongly disagree) to 5 (strongly agree); item scores are converted (odd-numbered items: response minus 1; even-numbered items: 5 minus response), summed and multiplied by 2.5. Total score ranges from 0 to 100. Higher scores indicate better perceived usability (better outcome).

    Measured: Week 8

  9. Negative effects of treatment (Negative Effects Questionnaire, 20-item version, NEQ-20)

    Negative effects of treatment measured with the 20-item version of the Negative Effects Questionnaire (NEQ-20). For each item, participants indicate whether the negative effect occurred and, if so, rate its impact from 0 (not at all) to 4 (extremely) and attribute it either to the treatment or to other circumstances. The total score is the sum of the 20 items, ranging from 0 to 80. Higher scores indicate more frequent and more severe negative effects (worse outcome).

    Measured: Week 8

  10. Global impression of change (Patient Global Impression of Change, PGIC)

    Participants' overall impression of change since starting the intervention (Week 0), measured with a single global change item rated on a 7-point scale from 0 (very much worse) to 6 (very much improved)]. A higher score indicates greater perceived improvement (better outcome).

    Measured: Week 4, Week 8, 3 months follow-up, 6 months follow-up

  11. Awareness of Processes Post-Intervention Scale

    Participants' awareness of the therapeutic processes targeted by the intervention, measured with the Awareness of Processes Post-Intervention Scale, a study-specific [N]-item self-report measure. Each item is rated from 1 (not at all true) to 5 (very much true) and items are summed, giving a total score range of 9 to 45. Higher scores indicate greater awareness of the targeted processes.

    Measured: Week 8

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2026
  2. Study start15 Sep 2026
  3. Primary completion30 Sep 2027 (estimated)
  4. Study completion30 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07814196
Sponsor's protocol ID
iACTforDGBI_RCT
Acronym
iACTforDGBI
Status last verified
Oct 2026
First submitted
2 Sep 2026
Last updated
23 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing iACTforDGBI intervention and DGBI School in people with Disorders of Gut-brain Interaction and Distress, Psychological, run by Örebro University, Sweden at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Depressive symptoms (Patient Health Questionnaire-9, PHQ-9) (time frame: Week 0, Week 4, Week 8, 3 months follow-up, 6 months follow-up). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in